Following job cuts and R&D restructuring, microcap microRNA player miRagen brings in new CEO to right the ship

Four years after riding the shell of a struggling microcap biotech to Nasdaq with $40 million in cash, microRNA player miRagen Therapeutics is facing a reckoning of its own.

After the market close Thursday, miRagen disclosed a flurry of changes at the company: CEO William Marshall has resigned, leaving COO Lee Rauch in charge as the new chief to oversee a “review of strategic alternatives” — often a sign that the board is eager for a sale, although in-licensing and other deals are also on the table.